Saiid Zarrabian

WORK HISTORY

SKILLS

ABOUT SAIID ZARRABIAN

Located in San Diego, California, Kintara Therapeutics is focused on the development and commercialization of new therapies for cancer patients who have limited or no treatment options. By focusing on understanding tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize new therapies in indications where patients are failing, or are unable to tolerate, standard-of-care treatments. The Company’s current pipeline is based around VAL-083, a \"first-in-class”, small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara\'s’s internal research programs and these prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support the development and commercialization of VAL-083 to solve significant unmet medical needs, with the lead indication in GBMWe are additionally initiating a Phase 3 study with REM-001, our just acquired photo dynamic therapy with lead indication in CMBC (Cutaneous Metastatic Breast Cancer)VAL-083 is being studied in two collaborator-supported, biomarker-driven Phase 2 clinical trials for MGMT-unmethylated GBM. Overcoming MGMT-mediated resistance represents a significant unmet medical need in the treatment of GBM. Further information on Kintara’s clinical trials can be found on clinicaltrials.gov: & term=val-083 & cntry1= & state1= & recrs For additional information, please visit http://Kintara.com/; or contact Kintara Therapeutics Investor Relations: i•••@Kintara.com /(60••••••89.